Business Standard

Cipla expects surge in demand for respiratory drugs, inhalers in winter

The firm enjoys a massive 68.7 per cent market share in the respiratory inhalation segment in India and has started working on aligning supplies so that there is no shortage of these critical medicine

Cipla, Cipla logo, Cipla headquarters
Premium

Sohini Das Mumbai
Cipla, the market leader in respiratory therapies, expects a surge in demand for respiratory drugs and inhalers during the coming months when the winter and an anticipated second Covid wave are likely to push up demand for these medicines.
 
The firm enjoys a massive 68.7 per cent market share in the respiratory inhalation segment in India and has started working on aligning supplies so that there is no shortage of these critical medicines.
 
During this time, pollution levels (especially in north India) and other environmental factors cause a surge in respiratory illnesses. Cipla aspires to become the global lungs leader

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in